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Abstract
Otitis media (OM) is a highly prevalent pediatric disease caused by normal flora of the nasopharynx that ascend the
Eustachian tube and enter the middle ear. As OM is a disease of opportunity, it is critical to gain an increased understanding
of immune system components that are operational in the upper airway and aid in prevention of this disease. SPLUNC1 is
an antimicrobial host defense peptide that is hypothesized to contribute to the health of the airway both through
bactericidal and non-bactericidal mechanisms. We used small interfering RNA (siRNA) technology to knock down expression
of the chinchilla ortholog of human SPLUNC1 (cSPLUNC1) to begin to determine the role that this protein played in
prevention of OM. We showed that knock down of cSPLUNC1 expression did not impact survival of nontypeable
Haemophilus influenzae, a predominant causative agent of OM, in the chinchilla middle ear under the conditions tested. In
contrast, expression of cSPLUNC1 was essential for maintenance of middle ear pressure and efficient mucociliary clearance,
key defense mechanisms of the tubotympanum. Collectively, our data have provided the first in vivo evidence that
cSPLUNC1 functions to maintain homeostasis of the upper airway and, thereby, is critical for protection of the middle ear.
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Introduction
Otitis media (OM), or inflammation of the middle ear, is the
second most common pediatric infectious disease. Over 80% of
children develop a least one incident of OM by three years of age
and more than half of children experience multiple episodes of this
disease [1,2]. OM is the leading cause for physician office visits and
pediatric surgeries and is the most frequent reason for the
prescribing of antibiotics. Indeed, the estimated cost per episode of
OMintheUSisinthe hundredsofdollars andmorethan15million
antibiotic prescriptions are written each year for the treatment of
OM. Further, the total cost of diagnosis and management of OM
exceeds $5 billion annually in the US alone which serves to
underscore the need to develop more effective preventative and
therapeutic strategies for this prevalent disease [3,4,5,6].
OM is not caused by highly virulent microorganisms, but is
instead induced by a subset of commensal bacteria that comprise
the normal flora of the pediatric nasopharynx. Three bacterial
species (nontypeable Haemophilus influenzae [NTHI], Streptococcus
pneumoniae, and Moraxella catarrhalis) are commonly isolated from
middle ear effusions, with the greatest number of cases of OM with
effusion caused by NTHI [7,8]. When host airway defenses are
compromised, most typically by upper respiratory tract (URT)
viruses, these bacteria can behave as opportunistic pathogens and
ascend the Eustachian tube (ET) to gain access to the middle ear
[9,10,11]. As such, it is important to understand and characterize
host defense mechanisms that contribute to prevention of OM and
promote overall health of the uppermost respiratory tract.
In the mammalian airway, there are multiple first lines of
defense that include mucociliary clearance, trapping functions of
mucus glycoproteins and action of surfactants [12]. Several
surfactant proteins are produced in the ET and these proteins
serve to lower surface tension at the mucosal surface, an important
parameter for optimal ET function [12]. Additionally, some of
these surfactant proteins are members of the antimicrobial host
defense family of proteins (APs) and protect mucosal surfaces by
direct agglutination and opsonization of microorganisms [12]. The
AP family of proteins, which also includes lysozyme, lactoferrin,
cathelicidins, peptidoglycan recognition proteins, and b-defensins,
are key components of the primary defense system and can
inactivate bacteria, fungi and viruses on epithelial surfaces that line
the respiratory tract [13,14,15,16,17]. We have previously
demonstrated that the chinchilla, a predominant host used to
model human OM, produces several APs in the upper airway
including a b-defensin, and that expression of this defensin at the
mucosal surface directly impacts the ability of NTHI to colonize
the nasopharynx [18]. Collectively, these data provide evidence
that effectors of innate immunity are produced at sites relevant to
OM and suggest that these proteins likely play a critical role in
defense of the middle ear.
The SPLUNC1 protein, a recently described AP, is a
predominant constituent of surface liquid that covers mucosal
surfaces of the human respiratory tract [19,20]. SPLUNC1 is a
secreted protein and has been detected in both nasopharyngeal
lavage (NL) fluid [21] and sputum [22]. This AP is produced by
mucosal tissues of the airway including the nasal septum, ethmoid
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cally, SPLUNC1 is predominately produced by mucous cells and
submucosal glands, although expression by epithelial cells of the
upper airway has also been reported [19,23]. With regards to
SPLUNC1 function, purified recombinant protein can kill bacteria
and also reduce biofilm formation by Pseudomonas aeruginosa in vitro,
supporting the assertion that this molecule functions in host defense
[19,20,25,26,27]. In addition, SPLUNC1 is a multifunctional
protein that serves to protect the sodium channel protein ENaC,
which regulates airway surface liquid volume, from proteolytic
cleavage. Effective maintenance of mucosal liquid volume,
mediated by appropriate expression of SPLUNC1, is thought to
promote mucociliary clearance of microorganisms in the airway
[20], a key host defense mechanism utilized in protection of the
middle ear [9]. Additionally, human SPLUNC1 has been reported
to act as a surfactant to reduce surface tension at an air-liquid
interface [28], thus providing an additional mechanism by which
this AP likely contributes to proper airway function. Altogether,
data obtained from these in vitro analyses suggests that SPLUNC1 is
an AP operational at mucosal surfaces that likely promotes health of
the airway through bactericidal and non-bactericidal mechanisms.
As SPLUNC1 is postulated to play a role in host defense against
microorganisms, we utilized small interfering RNA (siRNA)
technology to knock down expression of the chinchilla ortholog of
human SPLUNC1 (cSPLUNC1) and determined the impact of
altered cSPLUNC1 expression on the development of experimental
OM induced by NTHI. Under the conditions tested, chinchillas
administered a cSPLUNC1-specific siRNA, then directly challenged
with NTHI in the middle ear did not show a significant difference in
the concentration of bacteria within the tympanum, compared to
animals that received a control siRNA that did not modulate
expression of cSPLUNC1. In contrast however, reduced cSPLUNC1
expression had a major impact on ET function as evidenced by a
pronounced deficiency in the ability of this organ to maintain proper
middle ear pressure or mediate effective mucociliary clearance,
compared to controls. We thus provided evidence that ET
dysfunction observed in animals with diminished cSPLUNC1
expression was likely due to the intrinsic ability of this AP to function
as a biological surfactant. Collectively, our data suggested that the
surfactant activity of cSPLUNC1 was essential for homeostasis of the
uppermost airway and therefore, defense of the middle ear.
Results
Cloning of cSPLUNC1 cDNA
To begin to determine the role that SPLUNC1 might play
in prevention of bacterial OM, we cloned a 792 bp cDNA
that encoded the chinchilla ortholog of human SPLUNC1
(cSPLUNC1). The cSPLUNC1 cDNA was predicted to encode a
263 amino acid protein with an abundance of hydrophobic residues
(117 amino acids, 44%) and a molecular mass of 27.3 kDa.
CLUSTAL W analysis of the deduced cSPLUNC1 amino acid
sequence demonstrated strong conservation with human (74.6%
identity) and rat (68.6% identity) SPLUNC1 [supporting informa-
tion (SI) Fig. S1]. In addition, bioinformatic tools predicted that
cSPLUNC1, similar to human SPLUNC1, was a secreted protein
(Fig. S1). Collectively, these data suggested that cSPLUNC1 likely
shared activities with human SPLUNC1 such as the ability to kill
bacteria [25,26] and act as a surfactant in vitro [29].
Determination of relative expression of cSPLUNC1 mRNA
and protein in chinchilla tissues
To enable our ability to attempt to knock down expression of
cSPLUNC1 in vivo, it was necessary to first identify tissues in the
upper airway that expressed cSPLUNC1. We therefore isolated
total RNA from several URT tissues and used RT-PCR to amplify
cSPLUNC1 transcripts. cSPLUNC1 mRNA was detected in each
URT sample evaluated which included mucosa from the nasal
septum, nasoturbinate, ethmoid turbinate, nasopharynx, Eusta-
chian tube, and middle ear (Fig. 1A). We also amplified b-actin
from these same tissues as a control (Fig. 1A).
To complement our analysis of cSPLUNC1 mRNA expression,
we used Western blot to detect cSPLUNC1 protein in the
chinchilla upper airway. We reasoned that antibodies directed
against human SPLUNC1 would also detect cSPLUNC1, and
indeed demonstrated that this antiserum recognized recombinant
cSPLUNC1 [(r)cSPLUNC1] (Fig. 1B). As a reference, we also
detected recombinant human SPLUNC1 in the same immunoblot
(Fig. 1B). We subsequently showed that native cSPLUNC1 was
produced in mucosa of the nasal septum, nasoturbinate, ethmoid
turbinate, nasopharynx, Eustachian tube, and middle ear (Fig. 1B),
a finding that was in full agreement with results obtained from our
RT-PCR analysis. In addition, we demonstrated that cSPLUNC1
was secreted in the airway by detection of this protein in chinchilla
NL fluids (Fig. 1C). Interestingly, recombinant cSPLUNC1
separated by SDS-PAGE did not exhibit the same mobility as
native cSPLUNC1. This observation was due to the absence of
eukaryotic post-translation modifications such as glycosylation
which has been reported for human SPLUNC1 present in NL
fluid [30] and which we have obtained evidence for native
cSPLUNC1 (McGillivary et al, unpublished). Collectively, our
results demonstrated that cSPLUNC1 was produced at several
mucosal sites in the chinchilla URT and suggested that these
tissues were indeed appropriate targets for attempting to silence
cSPLUNC1 expression.
Administration and detection of siRNA in the chinchilla
upper airway
siRNA has not previously been used in the chinchilla host to
generate a knock down in gene expression. As such, it was
necessary for us to develop an siRNA approach to knock down
expression of cSPLUNC1 in vivo. Chinchillas were intranasally and
transbullarly administered 10 nmoles of a siRNA labeled with
alexafluor-647 and fluorescence was subsequently monitored in
the airway. We first used a non-silencing siRNA to minimize any
impact that gene knock down might have on our ability to track
the nucleic acid in vivo. We detected siRNA in the nasal cavity and
middle ear of chinchillas immediately after delivery of the
molecule to these sites (Fig. 2A), whereas no fluorescence was
detected in animals that did not receive siRNA (data not shown).
Three hours after administration of siRNA, we sacrificed a
chinchilla to determine the precise location of siRNA within the
nasal cavity. Fluorescence was readily observed in the nasoturbi-
nates and as far retrograde as the nasopharynx, but was not noted
in the ethmoid turbinates (Fig. 2B). The computer software used in
this analysis scales output to the greatest signal measured within a
single scan and therefore we reasoned that the observed very
strong fluorescence in the nasoturbinates could have masked
weaker fluorescence in the ethmoid turbinates. Therefore, we
covered the nasoturbinates to block fluorescence from this tissue
and were now able to show that siRNA was indeed delivered to the
ethmoid turbinates (Fig. 2C). To provide evidence that siRNA not
only reached sites of cSPLUNC1 expression but also entered
epithelial cells where gene silencing is mediated, we demonstrated
by fluorescence microscopy that delivery of siRNA to the
chinchilla nasal cavity resulted in the presence of siRNA within
the cytoplasm of epithelial cells of the upper airway (Fig. 2D).
Knocking Down SPLUNC1
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animals were imaged one, two, four, and five days after
administration of the molecule. We detected fluorescence in the
nasal cavity of chinchillas for at least five days (Fig. 2E left panel)
and for a minimum of two days in the middle ear (data not shown).
Upon sacrifice of chinchillas five days after delivery of siRNA, we
demonstrated by ex vivo imaging that siRNA was indeed present in
the middle ear, in excised middle ear mucosa, and in ET tissues
(Fig. 2E right panel). These results demonstrated that siRNA
delivered to the nasal cavity and middle ear of chinchillas was
maintained in these tissues for a minimum of five days and
suggested that a knock down in cSPLUNC1 gene expression could
likely be similarly maintained for this duration.
Determination of cSPLUNC1 knock down in vivo
To now demonstrate that we could indeed silence cSPLUNC1
expression in the airway, we intranasally administered to
chinchillas one of several doses (0.05, 0.5, 5, or 10 nmoles) of
two unique siRNAs that were designed to knock down expression
of cSPLUNC1. We collected NL fluids from chinchillas before
siRNA treatment to determine baseline cSPLUNC1 expression in
these animals and used Western blot to determine protein
expression over time. We did not observe a significant decrease
in cSPLUNC1 expression when 0.05, 0.5, or 5 nmoles of siRNA
(cSPLUNC1 siRNA #1o r#2) was administered to chinchillas
(data not shown). In contrast, delivery of 10 nmoles of siRNA #1
to the nasal cavity resulted in diminished expression of
cSPLUNC1 after one and five days after delivery of siRNA, when
compared to cSPLUNC1 abundance from the same animal before
administration of siRNA (Fig. 3A). Delivery of siRNA #2 resulted
in a more modest and delayed reduction in cSPLUNC1
expression, while administration of 10 nmoles of negative control
siRNA did not result in a detectable reduction in cSPLUNC1
expression at any time point evaluated (Fig. 3A).
To provide additional evidence for siRNA-mediated knock
down in cSPLUNC1 expression, we analyzed cSPLUNC1 mRNA
expression in nasoturbinate mucosae of the upper airway one day
after delivery of siRNA to chinchillas (n=3 animals per cohort).
RT-PCR analysis demonstrated that administration of
cSPLUNC1 siRNA #1 resulted in a 52% reduction (p=0.004),
whereas delivery of cSPLUNC1 siRNA #2 resulted in a 25%
reduction (p.0.05) in cSPLUNC1 mRNA expression, compared
to animals that received the negative control siRNA (Fig. 3B and
C). Collectively, these data provided the first demonstration of a
gene knock down in the chinchilla.
Purification of native cSPLUNC1 and determination of its
ability to kill NTHI
As stated earlier, SPLUNC1 is a multifunctional protein that is
able to kill bacteria [20,25,26,27,28,30]. As NTHI is a
predominant causative agent of OM, we first demonstrated that
isolated native cSPLUNC1 was able to kill NTHI in vitro (Fig. 4A,
B, C, D, and E). We showed that our purified protein reacted with
SPLUNC1-specific antiserum in Western blot (Fig. 4B) and
capillary-liquid chromatography-nanospray tandem mass spec-
trometry (LC/MS/MS) analysis provided sequence which
matched 75 of the 263 amino acids predicted from the
cSPLUNC1 cDNA sequence. Further, we used circular dichroism
Figure 1. cSPLUNC1 mRNA and protein expression in the chinchilla upper airway. (A) RT-PCR analysis of (top panel) cSPLUNC1 or (bottom
panel) b-actin transcripts in multiple chinchilla tissue homogenates. b-actin mRNA was amplified to confirm that equal amounts of template RNA was
used in the amplification process. Amplicons generated with reverse transcriptase (+) or without reverse transcriptase (2) were separated in an
ethidium bromide-stained agarose gel. (B) We used anti-human SPLUNC1 in Western blot to detect native cSPLUNC1 in selected mucosal
homogenates. Recombinant cSPLUNC1 [(r)cSPLUNC1] was also detected to provide evidence that the antisera used in this analysis recognized the
chinchilla ortholog of human SPLUNC1 and recombinant human SPLUNC1 [(r)hSPLUNC1] served as the positive control in this analysis. (C) Proteins in
nasopharyngeal lavage fluid were separated by SDS-PAGE and Western blot was used to detect secreted cSPLUNC1 in the upper airway. cSPLUNC1
mRNA and protein was detected in every URT tissue evaluated.
doi:10.1371/journal.pone.0013224.g001
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similar to a published report for recombinant human SPLUNC1
[28] with 67% of the molecule predicted to be alpha-helical, 3% as
a b-sheet, and 30% in a random coil conformation (Fig. 4D).
Interestingly, our purification scheme, that included electroelution
of ,25 kDa native cSPLUNC1 from SDS-PAGE gels, also
resulted in detection of a ,65 kDa band by SDS-PAGE
(Fig. 4C). This protein was also identified by LC/MS/MS (53 of
263 amino acids) as cSPLUNC1 which suggested that native
cSPLUNC1 was capable of forming a multimer in vitro.
After we demonstrated our ability to purify native cSPLUNC1,
we next assessed the bactericidal activity of native cSPLUNC1
against NTHI and showed that 1.3 mg native cSPLUNC1/ml
phosphate buffer was able to kill greater than 50% of a 1610
5
inoculum of NTHI in a one hour assay (Fig. 4). Our data also
demonstrated that native cSPLUNC1 was more effective in killing
NTHI than either the human cathelicidin LL-37 or lysozyme
(Fig. 4), two additional APs that are expressed in the upper airway
[31,32]. As it has been estimated that SPLUNC1 is expressed in
airway secretions at concentrations of 10–250 mg protein/ml fluid
[28], these data suggested that as typically produced in the normal
upper airway, cSPLUNC1 was likely able to kill NTHI in vivo.
Effect of cSPLUNC1 knock down on the development of
bacterial OM
We next determined the ability of cSPLUNC1 to impact NTHI
survival in the chinchilla middle ear. Two cohorts of animals (n=3
per cohort) were administered 10 nmoles of either a negative
control siRNA or cSPLUNC1 siRNA #1. Twenty-four hours
later, chinchillas were transbullarly challenged with NTHI and the
resultant middle ear effusions were collected 2 and 4 days after
bacterial challenge to determine the concentration of NTHI
present in these middle ear fluids. We showed that at the challenge
dose used (,1000 cfu NTHI/ear), the load of NTHI present in
effusions was not significantly different between animals that
received either control or cSPLUNC1 siRNA wherein approxi-
mately 1610
8 cfu NTHI/ml middle ear fluid were present two
days after bacterial challenge (Fig. 5). We also did not observe a
Figure 2. Detection of siRNA in the chinchilla upper airway. A negative control siRNA labeled with Alexafluor-647 was administered
intranasally and transbullarly to chinchillas and fluorescence was detected (A) immediately, (B, C, and D) three hours, or (E) five days after delivery of
siRNA. The images in (B and C) are of a sagittal section of a chinchilla head with tissues that express cSPLUNC1 identified by arrows. The
nasoturbinates in (C) are covered by black non-fluorescent paper to block the strong fluorescence from this tissue and to allow detection of the
weaker fluorescence from siRNA in the ethmoid turbinates and nasopharynx. (D) Nasoturbinate mucosae was embedded, sectioned, and stained with
phalloidin conjugated to FITC to detect actin (green) and DAPI to stain DNA (blue). The top panel shows the fluorescently-labeled siRNA (red) alone
and the bottom panel shows labeling for siRNA, actin, and DAPI. (E, right panel) Ex vivo analysis of the presence of siRNA in the tubotympanum. These
data demonstrated that siRNA entered epithelial cells of the upper airway and showed our ability to detect siRNA in the chinchilla nasal cavity,
Eustachian tube, and middle ear for at least five days after delivery of siRNA.
doi:10.1371/journal.pone.0013224.g002
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in the middle ears of animals four days after bacterial challenge
(Fig. 5).
In addition to culture data, we used tympanometry to provide
an indication of the relative severity of experimental OM in
animals challenged with NTHI. We monitored changes in middle
ear pressure (MEP) and tympanic membrane compliance (TMC),
or mobility of the tympanic membrane, to obtain quantitative
information on middle ear function. A tympanogram was
considered abnormal if middle ear pressure was $2100 daPa or
Figure 3. Knock down of cSPLUNC1 expression in vivo. (A) NL fluids were collected from chinchillas prior to administration of siRNA (d=0) or
after delivery of 10 nmoles of an siRNA. Two unique siRNAs that were designed based on the cDNA sequence of cSPLUNC1 and an siRNA that did not
have complementary sequence to cSPLUNC1 were intranasally delivered to chinchillas, and NL fluids were collected from animals one and five days
later. cSPLUNC1 protein present in NL fluids was detected by Western blot using rabbit anti-native cSPLUNC1 and knock down in expression was
determined by comparison of band intensities for each panel before and after delivery of siRNA. (B) The siRNA molecules utilized in (A) were
administered intranasally to chinchillas (n=3 per cohort) and 24 hours later animals were sacrificed, nasoturbinate mucosae was collected, and total
RNA was isolated. RT-PCR with primers designed to amplify (top panel) cSPLUNC1 or (middle and bottom panels) the control b-actin was used to
determine relative mRNA expression for the targets among the cohorts. Amplification was also done in the absence of reverse transcriptase to
demonstrate the absence of contaminating DNA as shown in the bottom panel. (C) Densitometric analysis of the intensity of RT-PCR amplicons
shown in (B). Administration of 10 nmoles of cSPLUNC1 siRNA #1 resulted in a significant reduction (asterisk) in cSPLUNC1 expression, compared to
the negative control siRNA.
doi:10.1371/journal.pone.0013224.g003
Knocking Down SPLUNC1
PLoS ONE | www.plosone.org 5 October 2010 | Volume 5 | Issue 10 | e13224$+60 daPa and compliance values were #0.5 or $1.2 ml [33].
Our tympanometric analysis demonstrated that chinchillas
administered cSPLUNC1-specific siRNA developed a strong
negative MEP compared to controls. Chinchillas [n=3 animals
(6 ears) per cohort] that received control siRNA demonstrated
both a normal average MEP value of 3612 daPa and compliance
value of 160.2 ml whereas chinchillas administered cSPLUNC1
siRNA exhibited an abnormally negative MEP of 2117612 daPa
and associated increased compliance value of 1.560.2 ml. The
difference in the average MEP and compliance values between the
two cohorts was statistically significant (p=0.0001 for MEP and
p=0.0001 for compliance). A representative image is shown in
Fig. 6A. The pronounced shift to a negative MEP with a
compliance value that was also abnormal, as assessed by the
relative height of the curve in the tympanogram, suggested that the
tympanic membrane was retracted and the mobility was thus
altered (i.e. reduced) in animals administered cSPLUNC1-specific
siRNA. We therefore directly visualized the middle ear cavity of
chinchillas by micro-CT analysis and indeed observed that the
tympanic membrane was retracted in animals that received
cSPLUNC1 siRNA, a result not seen with those that received
control siRNA (Fig. 6B). After challenge of chinchillas with NTHI,
MEP measured in animals that received the cSPLUNC1 siRNA
remained consistently more negative throughout the study
compared to animals that received a control siRNA (data not
shown). As a primary function of the ET is to equilibrate
atmospheric pressure between the middle ear and the nasophar-
ynx, these results suggested that silenced cSPLUNC1 expression in
animals with NTHI-induced OM resulted in ET dysfunction.
Determination of morphological changes in the
tubotympanum after cSPLUNC1 knock down
We next used a histological approach to begin to determine the
underlying mechanism for the defect in ET function that we
observed. Animals (n=2 per cohort) that received control siRNA
and were challenged with NTHI showed an inflammatory cellular
infiltrate within the lumen of the ET but a predominately
characteristic ciliated pseudo-stratified columnar epithelium with
infrequent goblet cells evident (Fig. 7A). These results are
consistent with what has been published previously when
chinchillas are directly challenged in the middle ear with NTHI
and an inflammatory host response is initiated [34]. In contrast,
ETs from animals that received cSPLUNC1 siRNA demonstrated
a more pronounced influx of immune cells, cellular debris and
accumulation of mucus in the lumenal space (Fig. 7B). Goblet cell
hyperplasia was also evident in the epithelium of the ET, and the
increased number of these cells likely contributed to the increased
presence of mucus in the ET lumen (Fig. 7B, asterisks). Decreased
surfactant activity in the airway can result in increased production
of mucins [35], and therefore our data suggested that the ET
dysfunction we observed in chinchillas with NTHI-induced OM
subsequent to silenced cSPLUNC1 expression was due to
decreased surfactant activity in this tubal organ.
Figure 4. Purification of native cSPLUNC1 and its ability to kill
NTHI. Secreted proteins obtained from washing the apical surface of
CNPEs (Fig. S2) with PBS were separated by SDS-PAGE and (A) silver
stained or (B) used in Western blot to show native cSPLUNC1.
Additionally, proteins collected from the surface of CNPEs were
separated by SDS-PAGE, and cSPLUNC1 was gel extracted, electroelut-
ed, and refolded to obtain native protein. (C) Purified cSPLUNC1 was
detected in a silver stained SDS-PAGE gel and (D) shown to exhibit
secondary structure as determined by circular dichroism analysis. (E)
NTHI 86-028NP was incubated with increasing concentrations of native
cSPLUNC1, LL-37, or lysozyme for 1 hour, and the number of surviving
colony forming units were determined. Native cSPLUNC1 demonstrated
bactericidal activity against NTHI in vitro which suggested that
cSPLUNC1 may also impact the ability of NTHI to survive in vivo.
doi:10.1371/journal.pone.0013224.g004
Figure 5. Effect of cSPLUNC1 knock down on the development
of OM induced by NTHI. Chinchillas (3 per cohort) were administered
either a control or cSPLUNC1 specific siRNA and challenged one day
later with NTHI. The load of NTHI in middle ear effusions was
subsequently determined two and four days after bacterial challenge.
Knock down in cSPLUNC1 did not significantly impact survival of NTHI
in the chinchilla middle ear under the conditions tested wherein a
rigorous challenge dose was used.
doi:10.1371/journal.pone.0013224.g005
Knocking Down SPLUNC1
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To provide evidence that cSPLUNC1 indeed exhibited
surfactant activity, we evaluated droplet contact angle to
determine the relative ability of native cSPLUNC1 to reduce
surface tension of water in vitro. In this approach, droplets of a
solution were incubated on a hydrophobic surface and the ability
of a protein to reduce surface tension was assessed by measuring
the diameter of a droplet. We determined that 100 mg native
cSPLUNC1/ml water demonstrated a 25% increase in the droplet
diameter compared to water alone (p=0.0003) (Fig. 8A and B).
SDS, a detergent, also exhibited surfactant activity and served as a
positive control (p,0.0001), while the negative control (lysozyme)
did not show a significantly increased droplet diameter, relative to
water (p.0.05). The greater ability of native cSPLUNC1 to act as
a surfactant, compared to water or lysozyme, was also observed by
reduced height of a native cSPLUNC1 droplet (Fig. 8C).
ForamorequantitativeanalysisofcSPLUNC1surfactantactivity,
we used the pendant drop method to directly measure surface
tension. Droplets of water or lysozyme (20 mg/ml, 100 mg/ml, or
500 mg/ml) exhibited a surface tension of approximately 72 mN/m
(Fig. 8D), results that were consistent with what is known from the
literature [36]. In contrast, we showed that native cSPLUNC1
exhibited a dose dependent reduction in droplet surface tension
wherein 20 mg cSPLUNC/ml water, the least concentrated sample
tested, resulted in a statistically significant difference in surface
tension (64 mN/m, p,0.0001), compared to water alone (Fig. 8D).
The positive control (SDS) demonstrated a surface tension value of
29 mN/m(p,0.0001), a value that wassimilar to the surface tension
of a droplet of native cSPLUNC1 when tested at a concentration
of 500 mg/ml (Fig. 8D) (p,0.0001). These results showed that
native cSPLUNC1, at estimated physiological concentrations [28],
could indeed act as a surfactant and further supported the conclu-
sion that, in the context of NTHI-induced OM, expression of
cSPLUNC1 and its associated surfactant activity was crucial for
proper ET function.
Impact of silencing cSPLUNC1 expression on mucociliary
clearance in the ET
One biological function of the ET is to prevent entry of fluid
and/or debris into the middle ear to promote proper functioning
of the tympanum. As mucociliary clearance is impacted by
expression of surfactant proteins [12], we next assessed the
Figure 6. Impact of cSPLUNC1 knock down on the tubotympa-
num. Chinchillas were administered either a control or cSPLUNC1-
specific siRNA and (A) tympanometry was used to determine middle ear
pressure and tympanic membrane compliance and (B) computed
tomography imaging was used to visualize the right middle ear cavity
of chinchillas 24 hours after delivery of siRNA (before challenge with
NTHI). The tympanic membrane in (B) was pseudo-colored red to
highlight the retraction of the tympanic membrane that occurred in
animals that received cSPLUNC1 siRNA. Other structural differences that
are observed between the left and right panels (ie. morphology of the
cochlea) are due to slight differences in the positioning of animals in
the scanner and do not represent pathological changes in the ears of
animals when expression of cSPLUNC1 was diminished. Images shown
in (A) and (B) are representative of results obtained from the respective
cohorts. Knock down of cSPLUNC1 resulted in a strong middle ear
under pressure as evidenced by marked retraction of the tympanic
membrane. EAC – external ear canal, ME- middle ear cavity, C- cochlea.
doi:10.1371/journal.pone.0013224.g006
Figure 7. Effect of cSPLUNC1 knock down on the histopathol-
ogy of the ET recovered from animals with NTHI-induced OM.
Chinchillas (n=2 per cohort) were administered either (A) a control or
(B) cSPLUNC1-specific siRNA and challenged one day later with NTHI.
After four days, animals were sacrificed and Eustachian tubes were
embedded and stained with hematoxylin and eosin. Asterisks in (B)
indicate goblet cells. Knock down in cSPLUNC1 expression in chinchillas
with OM induced by NTHI resulted in a pronounced influx of
inflammatory cells, accumulation of cellular debris and mucus, and
goblet cell hyperplasia in the ET.
doi:10.1371/journal.pone.0013224.g007
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were administered either a negative control or cSPLUNC1-
specific siRNA. Twenty-four hours after delivery of siRNA, we
measured time required for the ET of chinchillas (4 ears per
cohort) to transport a small bolus of Coomassie brilliant blue from
the inferior aspect of the middle ear to the nasopharyngeal orifice
of the ET (Fig. 9A). For animals that received saline, the average
dye transport time was 126610 seconds, whereas chinchillas that
received the mucociliary stimulator isoproterenol exhibited a
decreased transport time of 91616 seconds (p=0.009) (Fig. 9B).
This latter result was expected as isoproterenol is a b-adrenergic
stimulator known to increase ciliary beat frequency and thereby
promote mucociliary clearance in the ET [37]. Animals that
received negative control siRNA demonstrated a dye transport
time of 134617 seconds (p.0.05), similar to that of animals that
received saline alone (Fig. 9B). In contrast, delivery of cSPLUNC1
siRNA resulted in a statistically significant increase in time,
268656 seconds, required to translocate dye from the middle ear
to the nasopharynx (p=0.002). Thus, knock down of cSPLUNC1
expression resulted in an approximate 50% decrease in the ability
of the ET to transport dye, compared to animals that received
saline alone. Collectively, these results demonstrated that silenced
expression of cSPLUNC1, and therefore also the associated
reduced surfactant activity, diminished mucociliary clearance by
the ET.
Discussion
OM is a disease of opportunity wherein commensal bacteria
present in the pediatric nasopharynx ascend the ET and enter the
middle ear cavity, most typically after or concurrent with infection
by URT viruses [7]. As such, characterization of host mechanisms
that promote health of the uppermost airway provide important
insight into the pathogenesis of OM and also help elucidate host
factors that contribute to the prevention of this highly prevalent
disease. In the mammalian airway, effectors of innate immunity
such as APs defend mucosal surfaces and act to protect a host
through bactericidal and non-bactericidal mechanisms [14,15].
SPLUNC1 is an AP that is abundantly expressed in the upper
airway [28], however the role that this protein might play in
prevention of OM is not completely understood. Here, we utilized
a siRNA-based approach to knock down expression of the
chinchilla homologue of human SPLUNC1 and thereby demon-
strated that this AP was critical for homeostasis of the
tubotympanum.
As a first step in the knock down of cSPLUNC1 expression, we
initially determined if we could deliver siRNA to tissues that
expressed cSPLUNC1 and also assessed the length of time the
molecule remained resident within the airway. We administered a
fluorescently-labeled siRNA to the chinchilla URT and deter-
mined that we could detect this siRNA in the middle ear and nasal
cavity. Specifically, intranasal administration of siRNA to the
chinchilla airway allowed for detection of the molecule in the
nasoturbinates, ethmoid turbinates and nasopharynx- sites known
to express cSPLUNC1. After intranasal and transbullar adminis-
tration of siRNA, we were able to detect fluorescence in the
chinchilla nasal cavity for at least five days and could also observe
fluorescence ex vivo in a dissected middle ear, excised middle ear
mucosa, and ET tissues. Our results demonstrated that siRNA
remained resident in the nasal cavity and middle ear for several
Figure 8. Surfactant activity of native cSPLUNC1. The relative ability of a droplet of water, lysozyme, native cSPLUNC1 or SDS to exhibit
surfactant activity was determined via (A, B, and C) contact angle or (D) pendant drop tensiometry analysis. SDS was used as a positive control for
surfactant activity whereas water and lysozyme served as the negative controls. (A, B, and C) Droplets of the four solutions were incubated on a
hydrophobic surface and images from a (A) top or (C) side view were collected. (B) The diameter of each droplet was measured in millimeters (n=4)
and compared, as a percentage, to the water control which was set to a value of zero. (D) Surface tension of the four solutions was determined (n=5)
and the mean 6 standard deviation presented. Asterisks denote a statistically significant difference (p,0.05) in values between samples and the
water alone control. Similar to SDS, native cSPLUNC1 reduced surface tension of water and suggested that this AP acted as a surfactant in vivo.
doi:10.1371/journal.pone.0013224.g008
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cSPLUNC1 knock down for this length of time in vivo. Indeed, we
demonstrated that administration of cSPLUNC1-specific siRNA
to the chinchilla airway resulted in a pronounced reduction in
cSPLUNC1 mRNA and protein expression after one day and
showed that protein expression was diminished for at least five
days. It will be interesting to determine the total length of time that
siRNA could be maintained in the nasal cavity, middle ear, and
ET, as it has been reported that knock down of a target can last
days to weeks depending on the dosing regimen [38].
Our data have provided the first demonstration of a successful
gene knock down in the chinchilla host, and have further allowed us
theopportunitytobegintoassessthe rolethatcSPLUNC1playedin
experimental OM induced by NTHI. Although purified native
cSPLUNC1 killed NTHI in vitro, the concentration of NTHI in
middle ear fluids after transbullar challenge was not increased by a
knock down in cSPLUNC1 expression, compared to controls. We
speculate that the discrepancy between the in vitro and in vivo
bactericidal activity of cSPLUNC1was likely due to the substantial
growth of NTHI in middle ears following the robust challenge dose
used here (ie. ,1000 cfu NTHI/ear), where the bacterial load
typically reaches ,1610
8 cfu NTHI per ml of middle ear fluid
within 48 hours. We are currently determining the role that
cSPLUNC1 has on the ability of NTHI to colonize the chinchilla
nasal cavity as the load of NTHI in this compartment (,1610
4 cfu
NTHI per ml NL fluid) is substantially less than that present within
the middle ear after direct, transbullar challenge [18].
Interestingly, knock down in expression of cSPLUNC1 resulted
in marked morphological and functional changes in the ET.
Animals that were administered cSPLUNC1-specific siRNA
showed a greater influx of immune cells into the ET lumen,
compared to controls. Human SPLUNC-1 binds bacterial
lipopolysaccharide which is thought to dampen the pro-inflam-
matory response [30], and this activity could explain the increased
abundance of white cells in the ET. However, we could not detect
a significant difference in expression of the pro-inflammatory
cytokines IL-1, IL-6, IL-8, IFN- c, or TNF-a in middle ear
effusions from animals that received either control or cSPLUNC1-
specific siRNA (data not shown), and therefore the underlying
mechanism responsible for the increased presence of leukocytes in
the ET remains to be described.
Silencing cSPLUNC1 expression in chinchillas with NTHI-
induced OM also resulted in an inability of animals to properly
equilibrate pressure between the middle ear and nasopharynx
which contributed to retraction of the tympanic membrane, and
also showed a greater accumulation of mucus in the ET lumen,
compared to controls. It is known that diminished surfactant
activity in the ET decreases the ability of this tubal organ to open
effectively which results in impaired pressure regulation in the
middle ear [12]. Also, it has been reported that surfactant protein
C-deficient mice challenged with Pseudomonas aeruginosa augment
mucin expression in the lung, compared to wild-type animals [35].
As we have demonstrated that cSPLUNC1 significantly affected
surface tension in vitro, our data collectively suggested that
cSPLUNC1 acted as a surfactant in vivo and that this activity of
cSPLUNC1 was critical for proper ET function. We suggest that
decreased surfactant activity in ETs from animals that received
cSPLUNC1 siRNA also contributed to the diminished effective-
ness of the ET mucociliary system since surfactants are known to
have a major impact on this function [12]. We demonstrated that
silencing cSPLUNC1 expression resulted in a 50% increase in the
time required for the ET to transport a small bolus of dye from the
middle ear to the nasopharynx. As mucociliary clearance is
affected by rheological properties of the mucus blanket [9], it is
likely that the increased mucus production in the ET of animals
that received cSPLUNC1 siRNA contributed to the results that we
observed. In addition, diminished cSPLUNC1 activity and
therefore reduced surface liquid volume, in an ENaC-dependent
manner, would likely result in altered airway hydration which
could also impact mucociliary clearance [20].
A question remaining is why silencing cSPLUNC1 expression
resulted in such a pronounced altered biological function when
additional surfactant proteins are also produced in the Eustachian
tube [12,39,40]. We suggest that diminished expression of
cSPLUNC1 with its unique combination of activities that include
binding of pro-inflammatory bacterial molecules, lowering of
surface tension, and acting as a liquid volume sensor in the
airway resulted in the establishment of an environment that could
not be compensated for by the presence of additional surfactants,
at least during the time frame that we evaluated. In a similar
manner, investigators that utilize diverse animal models have also
reported that altered expression of even a single effector of innate
immunity can impact a disease course [41,42]. As cSPLUNC1
played such an important role in maintaining normal function of
the ET, we anticipate that cSPLUNC1 also contributes to the
ability of the ET to prevent microbes such as NTHI from
entering the middle ear as these microorganisms do not typically
cause OM without prior compromise of immune defense [9]. If
this hypothesis is indeed proven to be correct, then cSPLUNC1
expression would affect all three known physiologic functions of
the ET that include pressure regulation, prevention of mucus and
debris entry into the middle ear, and defense of the tympanum
from microbes [16].
Figure 9. Role of cSPLUNC1 in ET function. Chinchillas (4 ears per
cohort) were administered either saline, isoproterenol, cSPLUNC1 siRNA,
or a negative control siRNA followed by delivery of a very small volume
of dye into the middle ear cavity 24 hours later. The average transport
time 6 standard deviation (in seconds) required for dye to be
transported from the middle ear to the nasopharyngeal orifice of the
ET was determined for each cohort. Asterisks denote a statistically
significant (p#0.05) difference in dye transport time between the
cohort that received saline alone and the cohorts that received
isoproterenol or the cSPLUNC1 siRNA. Whereas the b-adrenergic
mucociliary stimulator isoproterenol increased transport time, knock
down in cSPLUNC1 expression conversely prolonged dye transport time
likely as a result of reduced surfactant activity which diminished ET
mucociliary clearance.
doi:10.1371/journal.pone.0013224.g009
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cSPLUNC1 is critical for proper ET function and serves to
maintain homeostasis of the middle ear. In addition, these data
also suggest that cSPLUNC1 contributes to normal protection of
the middle ear and thereby, plays a key role in prevention of OM.
Materials and Methods
Ethics Statement
All studies that involved chinchillas were performed under
protocol 01304AR, approved by The Research Institute at
Nationwide Children’s Hospital Institutional Animal Care and
Use (IACUC) Committee.
Animals
Healthy adult chinchillas (Chinchilla lanigera), were purchased
from Rauscher’s Chinchilla Ranch (LaRue, OH) and given
chinchilla chow (Cincinnati Lab and Pet Supply, Cincinnati,
OH) and water ad libitum. We collected NL fluids from animals
that were anesthetized with xylazine (2 mg/kg, Fort Dodge
Animal Health, Fort Dodge, IA) and ketamine (10 mg/kg,
Phoenix Scientific Inc., St. Joseph, MO).
Cloning of cSPLUNC1 cDNA
Human SPLUNC1 orthologs in the mouse, rat, and cow share
significant pair-wise amino acid identities [43], which suggested
that we could used PCR to amplify cSPLUNC1 cDNA. The
CloneMiner system (Invitrogen, Carlsbad, CA) was used to
construct a chinchilla cDNA library derived from pooled total
RNA isolated from tissues of the URT (nasal septum, nasoturbi-
nate, ethmoid turbinate, and nasopharynx). Total RNA was
isolated from individual mucosal samples as reported previously
[39] and suspended in a volume of 80 ml diethly pyrocarbonate-
water. Fifty microliters from each of four RNA samples were
combined into one tube, and the micropoly(A) purist system
(Ambion, Austin, TX) was used to enrich for mRNA. Total RNA
(211 mg), in a volume of 250 ml, was added to 250 mlo f2X
Binding Solution and the mixture was incubated with oligo(dT)
cellulose. Cellulose with bound mRNA was pelleted, washed twice
with Wash Solution 1 and 2, and RNA was eluted with 100 mlo f
RNA Storage Solution. An Agilent 2100 Bioanalyzer (Agilent,
Foster City, CA) was used to confirm the integrity of purified RNA
before and after mRNA enrichment. First strand cDNA was
generated from a reaction that contained 2.5 mg mRNA, a
CloneMiner biotin-attB2-Oligo(dT) primer (online supplement
Table S1), and Superscript II reverse transcriptase (Invitrogen).
E. coli DNA Ligase, DNA polymerase I, and RNase H were added
to samples at 16uC to produce second strand cDNA. An attB1
adapter (Table S1) was ligated to the 5-prime end of the double-
stranded cDNA, and the Qiaquick PCR purification system
(Qiagen, Valencia, CA) removed residual un-ligated adapters and
small (,100 bp) cDNA molecules.
The resultant cDNA was used in a Hotstart Pfu (Stratagene, La
Jolla, CA) PCR reaction with the primers human SPLUNC1-F
Internal (Table S1) and human SPLUNC1-R Internal (Table S1)
used to amplify a partial cSPLUNC1 cDNA (,300 bp).
Amplicons were cloned into pCR-BLUNT II topo (Invitrogen)
and transformed into E. coli Top10. We used M13 forward and
reverse primers to sequence plasmids from selected recombinants
that produced colonies on LB agar that contained 50 mg
kanamycin/ml. One clone with sequence homology to SPLUNC1
genes from other mammals was evaluated further. To obtain a
larger cSPLUNC1 cDNA clone, human SPLUNC1-F upstream
(Table S1) and chinchilla SPLUNC1-R internal (Table S1)
primers were utilized in a Hotstart Pfu PCR reaction with the
chinchilla cDNA library again used as template. An ,800 bp
fragment was cloned into pCR-BLUNT II topo and sequenced as
above. This plasmid (pGMSH-9) contained a DNA insert with
significant similarity to human SPLUNC1 but did not encode the
entire cSPLUNC1 open reading frame. Therefore, oligonucleo-
tides were designed from the 5-prime untranslated region of
cSPLUNC1 and the 3-prime untranslated sequence of the human
SPLUNC1 cDNA (chinchilla SPLUNC1-F upstream and human
SPLUNC1-R downstream [Table S1]). The complete 792-bp
cSPLUNC1 cDNA was PCR amplified and cloned in pCR-
BLUNT II topo to yield pGMSH-10. cSPLUNC1 cDNA
sequence was submitted to the GenBank database (http://www.
ncbi.nlm.nih.gov/Genbank/index.html) under accession number
FJ830605.
Computer algorithms were used to further analyze the deduced
amino acid sequence of cSPLUNC1. SignalP was used to identify
the signal peptide cleavage site and a DNASTAR CLUSTAL W
protein alignment was used to detect conserved regions between
chinchilla, human, and rat SPLUNC1 molecules.
Isolation of total RNA from chinchilla tissues and
performance of RT-PCR
Total RNA was prepared from frozen tissues as described [18].
For RT-PCR, chinchilla SPLUNC1-F (Table S1) and chinchilla
SPLUNC1-R (Table S1) at 0.5 mM each, with 2 nanograms of
total RNA, were used in 25 ml total volume amplification
reactions. As a control for loading of equal amounts of total
RNA in this analysis, RT-PCR reactions that contained primers
[chinchilla b-actin-F and chinchilla b-actin-R (Table S1)] to
amplify chinchilla b-actin (Genbank accession number
DQ826531) were also used. Amplicons generated from reactions
with or without reverse transcriptase, to confirm absence of
genomic DNA in RNA preparations, were separated in ethidium
bromide-stained 0.8% agarose gels.
Detection of cSPLUNC1 protein in the upper airway
Chinchilla tissues were homogenized in 0.5 ml sterile saline with
a 1 X solution of protease inhibitors (Roche, Indianapolis, IN).
Samples were centrifuged at 16,0006g for 1 minute and
supernatants were removed. We determined the protein concen-
tration of samples and equal amounts (30 mg) of protein were
separated by SDS-PAGE. Proteins were transferred to nitrocellu-
lose and blots were incubated with a 1:1,000 dilution of mouse
anti-human SPLUNC1 (R and D systems, Minneapolis, MN)
followed by a 1:10,000 dilution of a goat anti-mouse secondary
antibody conjugated to horseradish peroxidase. The chemilumi-
nescent ECL substrate (Amersham, Piscataway, NJ) allowed
capture of signal on film.
Ability to knock down expression of cSPLUNC1 in vivo
As an initial step towards the goal of generating a cSPLUNC1
knock down in the chinchilla upper airway, we first determined if
we could deliver siRNA to tissues that expressed cSPLUNC1. We
intranasally administered 10 nmoles of an Alexafluor 647-labeled
negative control siRNA (Qiagen, Valencia, CA) in a 200 ml
volume to animals via microaerosol sprayer (Wolfe Tory Medical,
Salt Lake City, UT). siRNA was also delivered transbullarly to
middle ears of chinchillas in a total volume of 200 ml saline. The
Xenogen IVIS Spectrum system (Caliper life sciences, Hopkinton,
MA) was used to detect the presence of fluorescently labeled
siRNA in the upper airway of the chinchilla immediately, 3 hours,
or 5 days after administration of siRNA.
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upper airway, one chinchilla that was administered fluorescently
labeled siRNA was sacrificed 3 hours later. Mucosa from the
nasoturbinates was dissected, frozen in O.C.T compound (Fisher
Scientific, Pittsburgh, PA), and sectioned. Slides were fixed
with cold acetone and non-specific binding was blocked with
image-iT FX signal enhancer (Invitrogen). A 200 nM solution of
FITC-conjugated phalloidin was used to label actin and DAPI
(49,69-diamino-2-pheynylindole) was used to label DNA. Sections
were viewed using a Zeiss Axiovert 200M microscope with
apotome, and images were captured with an Axiocam MRm
camera.
After establishment of an experimental approach to deliver
siRNA to the upper airway, we intranasally administered either
0.05, 0.5, 5, or 10 nmoles of negative control siRNA or one of two
siRNAs (cSPLUNC1 siRNA #1 and #2) designed to knock down
expression of cSPLUNC1. The sequence for the sense strand of
cSPLUNC1 siRNA #1 was GAAUUGAAAU UGCCCAUGtt
and the sequence for cSPLUNC1 siRNA #2 was GAAUAA-
CAUCAUCGAC UUAtt (Applied Biosystems, Foster City, CA).
We obtained NL fluids as previously described [44] one and five
days after delivery of siRNA. To detect cSPLUNC1, equal
amounts of protein (30 mg) in NL fluids were separated by SDS-
PAGE and Western blot was performed with a 1:500 dilution of
rabbit anti-native cSPLUNC1 as primary antibody (supporting
information (SI) Materials and Methods S1). Blots were then
incubated with a 1:10,000 dilution of a goat anti-rabbit secondary
antibody conjugated to horseradish peroxidase. The chemilumi-
nescent ECL substrate (Amersham, Piscataway, NJ) allowed
capture of signal on film. We could not provide a load control
for this analysis as an antibody that recognized an appro-
priate chinchilla protein secreted in the airway was not readily
available.
After determination of the optimal dose of siRNA required to
reduce cSPLUNC1 protein production, we next confirmed the
ability (or lack thereof) of these same siRNAs to diminish
cSPLUNC1 mRNA expression in vivo. We intranasally adminis-
tered 10 nmoles of cSPLUNC1 siRNA #1, cSPLUNC1 siRNA
#2, or negative control siRNA to chinchillas (n=3 per cohort)
and sacrificed animals 24 hours later. Nasoturbinate mucosae was
dissected, frozen in liquid nitrogen, and total RNA was prepared
as described [18]. RT-PCR was performed as described above and
a GS-800 calibrated densitometer (Bio-Rad, Hercules, CA) was
used to determine pixel intensity of amplicons generated by RT-
PCR. Mean values (6 standard deviation) of the densitometric
analysis were reported as the ratio of the pixel intensity of samples
from chinchillas that received either cSPLUNC1 siRNA #1o r#2
compared to animals that received negative control siRNA.
Statistical significance was calculated using a Student’s T-test and
was significance was accepted at a p-value of #0.05.
Purification of native cSPLUNC1
To provide an abundant source of native cSPLUNC1, we first
cultured primary cells derived from the chinchilla nasopharynx as
this tissue was shown to produce native cSPLUNC1. Chinchilla
nasopharyngeal epithelial cells (CNPEs) were allowed to polarize
(Materials and Methods S1) and the apical surface of cells were
washed every 2 days with 0.5 ml of PBS per well to recover
secreted cSPLUNC1. Proteins collected from the apical surface of
CNPEs were pooled and 5 ml of this sample was lyophilized
overnight, suspended in 300 ml 1 X SDS-PAGE buffer without b-
mercaptoethanol, and separated in a 15% SDS-PAGE gel. Native
cSPLUNC1 was excised and electroeluted from the gel slice for
1K hours at 100 Volts in a 3.5 kDa D-tube dialyzer (EMD, San
Diego, CA). Samples were dialyzed overnight against distilled
water and lyophilized. cSPLUNC1 was suspended in 200 ml water
and residual SDS was removed using a detergent removal column
(Millipore, Billerica, MA). cSPLUNC1 was denatured by addition
of 2 ml of suspension buffer (6 M guanidine-HCl, 20 mM Tris-
HCl pH 7.0, 500 mM NaCl) and dialyzed at 4uC against buffers
that contained a sequentially reduced amount of urea (6 M, 3 M,
1 M, 0.5 M, and 0.1 M) to promote the slow refolding of
cSPLUNC1. Native cSPLUNC1 was ultimately dialyzed against
water overnight, lyophilized, and suspended in water.
Antimicrobial activity of native cSPLUNC1
The liquid bactericidal assay used was performed essentially as
described [40]. The assay was conducted with increasing
concentrations of native cSPLUNC1, the human cathelicidin AP
LL-37 (Peprotech, Rocky Hill, NJ), or lysozyme (Fisher). Colony
forming units were counted, and percent killing was calculated
relative to identical cultures incubated with only sodium phosphate
buffer (pH 7.2) that contained 1% sBHI. Data from triplicate
assays were presented as mean percentage killed 6 standard
deviation relative to concentration of AP.
Determination of the effect of a cSPLUNC1 knock down
on NTHI survival in the chinchilla middle ear
NTHI is a predominant bacterial causative agent of OM that
has been extensively utilized in chinchilla models [44]. As such, six
chinchillas (two cohorts of three each) were used to assess the
outcome of cSPLUNC1 knock down on the ability of NTHI to
multiply and survive in the middle ear. Ten nanomoles of either a
control or cSPLUNC1-specific siRNA were administered trans-
bullarly, and all animals were challenged one day later with
approximately 1000 cfu of NTHI strain 86-028NP [44]. Tympa-
nometry was used to monitor for development and severity of OM
as measured by: changes in middle ear pressure, tympanic width,
and tympanic membrane compliance as described [45]. A
tympanogram was considered abnormal if middle ear pressure
was $2100 daPa or $+60 daPa, compliance values were #0.5 or
$1.2 ml, and/or tympanic width was $150 daPa [33]. Epitym-
panic taps were attempted two and four days after bacterial
challenge and collected fluids were maintained on ice until serially
diluted and cultured on chocolate II agar plates (Fisher,
Pittsburgh, PA). Bacterial counts were reported as the average
cfu NTHI/ml middle ear fluid.
Influence of a cSPLUNC1 knock down on morphology of
middle ears challenged with NTHI
Micro-computed tomography (CT) (GE Healthcare, Pittsburgh,
PA) imaging can be utilized to non-invasively monitor morpho-
logical changes within the middle ear cavity during development
of OM. As such, we captured images of the chinchilla middle ear
before administration of siRNA, one day after delivery of siRNA,
and just prior to sacrifice. Final imaging was completed four days
after bacterial challenge, which was five days after administration
of siRNA to chinchillas. Anesthetized animals were scanned at
80 kV with a 450 mA current and a 3-D rendering from 200
separate images was generated with a reconstruction utility
provided by the manufacturer. Images were exported as a tiff
file and the tympanic membrane was pseudo-colored red for
improved visualization.
Our micro-CT analysis of chinchillas administered cSPLUNC1
siRNA suggested that a reduction in cSPLUNC1 expression
diminished the ability of the ET to function correctly during
NTHI-induced OM. As such, we used a histological approach to
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received control or cSPLUNC1 siRNA. Four days after bacterial
challenge, bullae with the ET intact were removed and fixed in
2% paraformaldehyde overnight at 4uC. After fixation, samples
were decalcified in a solution of 0.1 M tris (hydroxymethyl)
aminomethane pH 6.95 and 0.35 M ethylenediaminetetraacetic
acid (EDTA). EDTA solution was changed every 48 hours until no
calcium was detected according to the method of Seilly et al. [46].
Once decalcified, samples were embedded in paraffin, 5 mm
sections were cut and mounted onto slides, and sections were
stained with hematoxylin and eosin. Images were captured with a
Zeiss Axiocam MRc camera attached to a Zeiss Axioskop 40
microscope (Carl Zeiss Inc., Thornwood, NY).
Surfactant activity of cSPLUNC1
The results that we obtained from our in vivo analysis suggested
that cSPLUNC1 exhibited surfactant activity. We therefore tested
the ability of purified native cSPLUNC1 to act as a surfactant
in vitro. One measure of surfactant activity is the ability to reduce
surface tension, thus promoting spread and reducing the contact
angle of a solution on a hydrophobic surface. Four microliter
droplets of water, 100 mg lysozyme/ml water (Fisher), 100 mg
native cSPLUNC1/ml water, or SDS (10%) (Fisher) were thereby
incubated on the hydrophobic surface of Parafilm M for one
minute at room temperature as reported [36]. SDS was used as a
positive control and lysozyme was used as a negative control as is
not known to exhibit surfactant activity [36]. The concentration of
cSPLUNC1 used in this analysis was based upon the estimate that
cSPLUNC1 is present in epithelial airway secretions at concen-
trations of 10–250 mg/ml [28]. Samples were imaged with
Brightfield optics on a Zeiss Stemi SV6 microscope. Diameter of
a droplet was measured in millimeters using Axiovision software
and values (n=4) were standardized to the average diameter of a
droplet of water and reported as the percentage increase in
diameter relative to the water control. Statistical significance was
determined using Student’s T-test and a p-value #0.05 was
considered significant.
We also used pendant drop tensiometry (Augustine Scientific,
Newbury, Ohio) to directly measure surface tension of a 1 ml
droplet of water, lysozyme, native cSPLUNC1, or SDS (10%).
Several concentrations of cSPLUNC1 or lysozyme diluted in water
(20 mg/ml, 100 mg/ml, and 500 mg/ml) were used in this
procedure. In this analysis, a droplet of one of the four solutions
was formed on the end of a capillary tip and digitally imaged. The
mean curvature of the solution was determined at over 300 points
along its surface, and surface tension was calculated from these
values. Tension measurements were determined five times for each
sample and mean values 6 standard deviation were reported.
Statistical significance was determined using Student’s T-test and a
p-value #0.05 was considered significant.
Impact of silencing cSPLUNC1 on ET mucociliary
clearance
Expression of surfactant proteins can promote effective
mucociliary clearance in the airway [12]. We therefore deter-
mined if cSPLUNC1 expression and its surfactant activity (or lack
thereof) affected mucociliary clearance in the URT. Chinchillas
were transbullarly administered (n=4 ears per cohort) saline, 10
nmoles of cSPLUNC1 siRNA or 10 nmoles of a negative control
siRNA. Twenty-four hours later, the time required to transport a
small bolus of 5% Coomassie brilliant blue (Fisher) solution,
prepared in pyrogen-free saline, from the inferior aspect of the
chinchilla middle ear cavity to the nasopharyngeal orifice of the
ET was assessed following a published protocol [37]. The ability
of chinchillas to transport dye from the middle ear to the
nasopharyngeal orifice of the ET is a direct indicator of the
mucociliary clearance capability of this tubal organ [37]. One
cohort of animals that did not receive siRNA was admini-
stered 150 ml of a 0.005% solution of isoproterenol (Sigma), to
increase ciliary beat frequency and mucociliary clearance,
and thus served as a positive control [37]. One hundred and
fifty microliters of dye was delivered transbullarly to all four
cohorts of chinchillas and the transport time for appearance of
dye at the nasopharyngeal orifice of the ET was measured in
seconds. A camera (Watec-231S, Watec, Orangeburg, NY)
equipped with a three inch otoscope (Sopro-Comeg, Tuttlingen,
Germany) was used to visualize the opening of the ET and images
were captured with computer software (VetDock 2.1, Med-Rx,
Largo, Florida). Statistically significant differences in dye
transport times between the cohort that received saline alone
and those cohorts that received either isoproterenol, negative
control siRNA, or cSPLUNC1-specific siRNA was calculated
using Student’s t-test with significance accepted at a p-value of
#0.05.
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Materials and Methods S1
Found at: doi:10.1371/journal.pone.0013224.s002 (0.06 MB
DOC)
Figure S1 In silico analysis of cSPLUNC1. DNASTAR Clustal
W alignment of cSPLUNC1 with human (accession no. AF70860)
and rat SPLUNC1 (accession no. NM172031). Numbers to the
left represent the amino acid number for the respective SPLUNC1
molecule and the arrow shows the putative signal sequence.
Chinchilla SPLUNC1 was an ortholog of human SPLUNC1.
Found at: doi:10.1371/journal.pone.0013224.s003 (7.14 MB TIF)
Figure S2 Growth of polarized chinchilla nasopharyngeal
epithelial cells (CNPEs) and detection of native cSPLUNC1.
Nasopharyngeal mucosa was recovered from a chinchilla and
transferred to a Transwell membrane. When the culture was
confluent, growth medium was removed from the apical surface to
promote polarization of cells. (A) Hematoxylin and eosin stain of
CNPEs cultured for 40 days at the air-liquid interface shows
cellular stratification and differentiation. (B) Section of embedded
CNPEs incubated with rabbit anti-cSPLUNC1 and goat anti-
rabbit IgG-AlexaFluor 488 to detect cSPLUNC1. The section was
also counterstained with the nuclear stain DAPI (blue). (C) Serial
section from (B) stained with periodic acid-Schiff-Alcian blue to
detect mucopolysaccharide-producing cells. Note that the cell
producing cSPLUNC1 (yellow arrow in B) was identified as a
mucin-producing goblet cell (black arrow in C) as indicated by the
red color.
Found at: doi:10.1371/journal.pone.0013224.s004 (0.76 MB TIF)
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